Made in Leiden

Academic and industrial life sciences research in Leiden has already yielded a number of new technologies and products. The following examples of marketed products and products in the pipeline illustrate the park’s commercial potential:

  • Ruconest™, a drug against hereditary angioedema. Ruconest™ was the first biotech product to be fully developed in the Netherlands, by Pharming. It is available in Europe and since 2014 also in the US.
  • Factor-V Leiden, the most prevalent genetic risk factor for venous thrombosis, was discovered at the LUMC.
  • Remicade® by Janssen Biologics for the treatment of auto-immune diseases (Crohn's disease, rheumatoid arthritis, Bekhterev's disease, psoriatic arthritis, ulcerative colitis and psoriasis) is being used by over 1 million patients in 91 countries.
  • Filgotinib Galapagos’ lead compound against rheumatoid arthritis showed excellent data in the phase IIB clinical trials. Consequently Galapagos stocks soared in June 2015.
  • Against the backdrop of a growing epidemic in West Africa in 2014, Janssen mobilized significant resources and expertise and collaborated with global health stakeholders to deliver a vaccine candidate. The biggest lesson the world has learned with Ebola is that it will return, and we have to be prepared for - and prevent - the next epidemic. Public health experts agree that the availability of an effective vaccine would be a crucial part of an integrated approach to protecting communities from the Ebola virus.
    By now Janssen’s vaccine candidate has been submitted to the WHO to be listed for emergency use (EUAL). This would make it available during a possible next Ebola outbreak. With its partner Bavarian Nordic, Janssen Vaccines has produced 2 million vaccine regimens so far, with the capacity to produce several million more as needed.

  • In 2007 the first clinical trial on antisense-mediated exon skipping, a potential novel genetic therapy for Duchenne muscular dystrophy (DMD) was successfully completed by the LUMC and Prosensa (nowadays BioMarin).
    The aim was to restore the reading frame of the dystrophin protein that is disrupted in DMD by inducing exon 51 skipping in the dystrophin pre-mRNA. This gave rise to a development portfolio of Kyndrisa, as well as three other first-generation follow-on development compounds for distinct DMD mutations.
    However in 2016 BioMarin decided to focus on the development of more effective next generation oligonucleotides for the treatment of DMD. 
  • And many more... Keep an eye on our news section.

Did you know that it takes ten to fifteen years to develop and market a new drug? Find out more about drug development in the Leiden Red Carpet videos.

View videos